Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD Dose Response of Salmeterol/Fluticasone pMDIs in Healthy Volunteers
NCT02232087Phase 1Completed
- Sponsor
- Kindeva Drug Delivery
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of salmeterol and fluticasone propionate in asthma and chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Kindeva Drug Delivery. Primary endpoints: Relative Potency Max Heart Rate up to 6 hours and Relative Potency QTcB Interval up to 6 hours. Started Jul 2014; status: completed.
02
Drugs
salmeterolfluticasone propionate
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02232087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232087.